HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Trimebutine

HCID 5573
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
39133-31-8
Standard SMILES
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C
InChIKey
LORDFXWUHHSAQU-UHFFFAOYSA-N
Molecular formula
C22H29NO5
Average molar mass
387.5 g/mol
Monoisotopic mass
387.20457303

Overview

3,4,5-trimethoxybenzoic acid [2-(dimethylamino)-2-phenylbutyl] ester is a trihydroxybenzoic acid.

Names & identifiers

Preferred name
Trimebutine
IUPAC
[2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate
English name
Trimebutine
Molecular formula
C22H29NO5
Molecular weight
387.47

Names & synonyms

trimebutine39133-31-8TrimebutinumTrimebutina2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoateTransacalmModulon2-Dimethylamino-2-phenylbutyl 3,4,5-trimethoxybenzoatQZ1OJ92E5RMaleate, TrimebutineMaleate Salt, TrimebutineSalt, Trimebutine Maleate
Show more names
3,4,5-TRIMETHOXYBENZOIC ACID 2-[DIMETHYLAMINO]-2-PHENYLBUTYL ESTERMebutinTRIMEBUTINAPI Trimebutinetrimebutine free baseTrimebutine USP/EP/BPTrimebutine hydrochlorideTRIMEBUTINE 0.787% GRANULESCholesterol hemisuccinate Tris salt
DTXSID4023707(+-)-TrimebutineRefChem:389346DTXCID503707A03AA05TM906254-309-2Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester

Database identifiers

CAS
39133-31-8、58997-89-0、58997-90-3
PubChem CID
5573
DTXSID
DTXSID4023707
ChEMBL
CHEMBL190044
ChEBI
CHEBI:94458
UNII
9RKX7S7WFY、QZ1OJ92E5R、U4UUZ24TRB
EC Number
254-309-2、261-548-6
Nikkaji
J15.812G、J304.096H、J304.097F

Properties

Computed structural propertiesFilling in

XLogP
4
Topological polar surface area
57.2 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
6
Rotatable bonds
10
Heavy atoms
28
Formal charge
0
Complexity
466

Experimental & physicochemical properties

DrugsPharmaceutical
SolubilityInsoluble
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point78-82
Collision Cross Section193.19 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
78 · 78-80°C
Boiling point
513.42 °C · 513.42°C (rough estimate)
Density
1.1998 · 1.1998 (rough estimate)
refractive index
1.5614 · 1.5614 (estimate)
storage temp.
2 · 2-8°C
solubility
Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Very Slightly)
form
Solid
pka
7.29 · 7.29±0.50(Predicted)
color
White to Off-White
Water Solubility
10 g/L · 10g/L
Merck
14 · 14,9699
Major Application
forensics and toxicologypharmaceutical (small molecule)veterinary
InChI
1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3
InChIKey
LORDFXWUHHSAQU-UHFFFAOYSA-N
SMILES
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c2ccccc2
CAS DataBase Reference
39133 · 39133-31-8(CAS DataBase Reference)
FDA UNII
1 OJ92E5R · QZ1OJ92E5R
ATC code
3 AA05 · A03AA05
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
312 · H312-H302-H332-H413
Precautionary statements
264 · P264-P270-P301+P312-P330-P501-P280-P302+P352-P312-P322-P363-P501-P261-P271-P304+P340-P312
PPE
95 · Eyeshields, Gloves, type N95 (US)
WGK Germany
3 · 3
HS Code
2922.19 · 2922.19.0900
Storage Class
11 · 11 - Combustible Solids
REACH Registrations
Active

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 61.5% (8 of 13) of all reports.

Warning

H302 (23.1%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 13 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

Chemical: Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester

REACH registered substance: Trimebutine (EC: 254-309-2)

Hazard Classes and CategoriesAcute Tox. 4 (23.1%)

Toxicology

Drug Induced Liver Injury · 4 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Trimebutine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Safety data

PPE
Eyeshields, Gloves, type N95 (US)
wgk
3
hs_code
2922.19.0900
Signal word
Warning
Symbol(GHS)
GHS07
Storage Class
11 - Combustible Solids
Hazard statements
H312-H302-H332-H413
REACH Registrations
Active
Precautionary statements
P264-P270-P301+P312-P330-P501-P280-P302+P352-P312-P322-P363-P501-P261-P271-P304+P340-P312

Chemistry & industry

Pharmacology

ATC Code · 2 items

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingProtein binding is minimal with 5% in vivo and in vitro to serum albumin.
Pharmacodynamics · 1 item

Trimebutine is a spasmolytic agent that acts directly on smooth muscle to modulate gastric motility. It shows a "dual function" that stimulates or inhibits spontaneous contractions depending on the concentration and prior contractile activity in the preparation. Targeting ion conductance that regulates GI motility, trimebutine inhibits the inward calcium currents and calcium-dependent potassium currents in a concentration-dependent manner. At lower concentrations (1-10uM), trimebutine depolarizes the resting membrane potential without affecting the amplitude of contractions, which is thought to be mediated by inhibition of outward potassium currents. It is also shown to activate T-type Ca2+ channel and increase gastric emptying, intestinal and colonic contractility. At higher concentrations (100-300uM), reduced amplitude of spontaneous contractions and action potentials is thought to be mediated by inhibition of L-type Ca2+ channels and inward calcium current. Trimebutine mediates a local anesthetic action by acting as a weak agonist at mu opioid receptors.

Mechanism of Action · 1 item

At high concentrations, trimebutine is shown to inhibit the extracellular Ca2+ influx in the smooth muscle cells through voltage dependent L-type Ca2+ channels and further Ca2+ release from intracellular Ca2+ stores. Trimebutine is suggested to bind to the inactivated state of the calcium channel with high affinity. Reduced calcium influx attenuates membrane depolarization and decrease colon peristalsis. It also inhibits outward K+ currents in response to membrane depolarization of the GI smooth muscle cells at resting conditions through inhibition of delayed rectifier K+ channels and Ca2+ dependent K+ channels, which results in induced muscle contractions. Trimebutine binds to mu opioid receptors with more selectivity compared to delta or kappa opioid receptors but with lower affinity than their natural ligands. Its metabolites (N-monodesmethyl-trimebutine or nor-trimebutine), are also shown to bind to opoid receptors on brain membranes and myenteric synaptosomes.

Biological Half-LifeThe elimination half life is approximately 1 hour following a single oral dose of 2mg/kg, and 2.77 hours following a single oral dose 200 mg.
Metabolism/Metabolites · 1 item

Trimebutine undergoes extensive hepatic first-pass metabolism. Nortrimebutine, or N-monodesmethyltrimebutine, is the main metabolite that retains pharmacological activity on the colon. This metabolite can undergo second N-demethylation to form N-didesmethyltrimebutine. Other main urinary metabolites (2-amino, 2-methylamino or 2-dimethylamino-2-phenylbutan-1-ol) can be formed via hydrolysis of the ester bond of desmethylated metabolites or initial hydrolysis of the ester bond of trimebutine followed by sequential N-demethylation. Trimebutine is also prone to sulphate and/or glucuronic acid conjugation.

MeSH Pharmacological Classification · 2 items

Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.

Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.

Absorption, Distribution and Excretion · 3 items

The free base form or salt form of trimebutine are rapidly absorbed after oral administration, with the peak plasma concentration reached after 1 hour of ingestion. The time to reach peak plasma concentration following a single oral dose of 200mg trimebutine is 0.80 hours.

Renal elimination is predominant while excretion into feces is also observed (5-12%). About 94% of an oral dose of trimebutine is eliminated by the kidneys in the form of various metabolites and less than 2.4% of total ingested drug is recovered as unchanged parent drug in the urine.

Trimebutine is most likely to be accumulated in the stomach and the intestinal walls in highest concentrations. The fetal transfer is reported to be low.

Applications

UsesTrimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain.

UsesTrimebutine is an opioid receptor agonist and an antispasmodic agent (1,2). It is used to treat acute and chronic abdominal pain.

Upstream & downstream products

Upstream raw materials

2-Amino-2-phenylbutyric acid

Additional notes

DefinitionChEBI: 3,4,5-trimethoxybenzoic acid [2-(dimethylamino)-2-phenylbutyl] ester is a trihydroxybenzoic acid.

Related reactions

2 records
New reaction record
HRID 1445952 reaction equation
HRID 1445952As reactant
HRID 1879077 reaction equation
HRID 1879077As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes